89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. More Details
Flawless balance sheet and overvalued.
Share Price & News
How has 89bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ETNB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ETNB's weekly volatility has decreased from 16% to 6% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ETNB underperformed the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: ETNB underperformed the US Market which returned 19.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is 89bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWhat Is The Ownership Structure Like For 89bio, Inc. (NASDAQ:ETNB)?
5 months ago | Simply Wall StHow Many 89bio, Inc. (NASDAQ:ETNB) Shares Did Insiders Buy, In The Last Year?
7 months ago | Simply Wall StWe're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely
Is 89bio undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ETNB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ETNB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ETNB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ETNB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ETNB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ETNB is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (4.2x).
How is 89bio forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ETNB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ETNB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ETNB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ETNB's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ETNB's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ETNB's Return on Equity is forecast to be high in 3 years time
How has 89bio performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ETNB is currently unprofitable.
Growing Profit Margin: ETNB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ETNB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ETNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETNB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ETNB has a negative Return on Equity (-26.26%), as it is currently unprofitable.
How is 89bio's financial position?
Financial Position Analysis
Short Term Liabilities: ETNB's short term assets ($222.5M) exceed its short term liabilities ($9.4M).
Long Term Liabilities: ETNB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ETNB is debt free.
Reducing Debt: ETNB has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ETNB has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ETNB has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 68.6% each year.
What is 89bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ETNB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ETNB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ETNB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ETNB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ETNB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rohan Palekar (54 yo)
Mr. Rohan Palekar serves as the Chief Executive Officer and Director at 89bio, Inc. since July 16, 2018. Mr. Palekar served as the Chief Executive Officer and President of Avanir Pharmaceuticals, Inc. sinc...
CEO Compensation Analysis
Compensation vs Market: Rohan's total compensation ($USD1.02M) is below average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Rohan's compensation has increased whilst the company is unprofitable.
|CEO & Director||2.5yrs||US$1.02m||no data|
|Chief Technical Operations Officer & Head of Quality||1.83yrs||US$630.52k||0% |
|Chief Medical Officer||2.08yrs||US$764.94k||0% |
|Chief Financial Officer||1.5yrs||no data||no data|
|COO & Chief Business Officer||2.67yrs||US$318.00k||0% |
Experienced Management: ETNB's management team is considered experienced (2.1 years average tenure).
|CEO & Director||2.5yrs||US$1.02m||no data|
|Director||0.58yr||no data||no data|
|Independent Director||2.75yrs||US$122.77k||0.39% |
|Independent Director||3yrs||US$8.33k||no data|
|Independent Chairman of the Board||0.83yr||no data||no data|
|Independent Director||2.75yrs||US$8.33k||0.0043% |
|Independent Director||2.75yrs||US$6.67k||no data|
Experienced Board: ETNB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.2%.
89bio, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: 89bio, Inc.
- Ticker: ETNB
- Exchange: NasdaqGM
- Founded: 2018
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$425.010m
- Shares outstanding: 19.88m
- Website: https://www.89bio.com
Number of Employees
- 89bio, Inc.
- 142 Sansome Street
- 2nd Floor
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ETNB||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Nov 2019|
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate i...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/18 23:17|
|End of Day Share Price||2021/01/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.